Dr. Uwe E. Reinhardt is an Independent Director of Boston Scientific Corporationrationration, since May 7, 2002. Dr. Reinhardt is the James Madison Professor of Political Economy and Professor of Economics and Public Affairs at Princeton University, where he has taught since 1968. Dr. Reinhardt is a senior associate of the University of Cambridge, England and serves as a Trustee of the Duke University Health System, H&Q Healthcare Investors, H&Q Life Sciences Investors and Hambrecht & Quist Capital Management LLC. He is the Commissioner of the Kaiser Family Foundation Commission on Medicaid and the Uninsured and a member of the boards of directors of Amerigroup Corporationrationration and Legacy Hospital Partners, Inc. During 2007 through 2009, he served as President of the International Health Economics Association. In October 2009, Dr. Reinhardt was awarded by Germany?s President the Bundesverdienstkreuz for his work in international health economics and policy
Age: 74 Director Since 2002 Ph.D
|Reinhardt received a Bachelor of Commerce degree from the University of Saskatchewan, Canada and a Ph.D. in economics from Yale University.|
The company has Return on Asset of 3.1 % which means that on every $100 spent on asset it made $3.1 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of (50.67) % meaning that it generated no profit with money invested by stockholders.
The company has 4.25 B in debt with debt to equity (D/E) ratio of 0.65 which is OK given its current industry classification. Boston Scientific Corporation has Current Ratio of 1.86 which is typical for the industry and considered as normal.
Entity SummaryBoston Scientific Corporationration develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific Corporation [BSX] is traded on New York Stock Exchange in USA. It is located in Natick, MA and employs 24,000 people. Filter other
|Click to run this filter|| |
Filter Other Insiders
| BSX NYSE
Boston Scientific Corporation
Boston Scientific Corporation has less than 43.4 (%) percent chance of experiencing financial distress in the next 2 years of operations.
Boston price boundaries
Promote Boston and Uwe Reinhardt